相关实验视频

Updated: Jan 10, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

FRA1通过可操作的转录网络驱动黑色素瘤转移

Xiaonan Xu¹, Vinesh Jarajapu², Manon Chadourne²

¹Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. xiaonan.xu@moffitt.org.

|November 25, 2025

概括

通过调节AXL,CDK6和FSCN1.1等关键基因,FRA1驱动黑色素瘤转移. 抑制这些点抑制了瘤的扩散和改善了生存率,为黑色素瘤患者提供了新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

转录失调是黑色素瘤进展的关键因素.
驱动黑色素瘤转移的分子机制尚未完全理解.
确定可操作的治疗点对于黑色素瘤治疗至关重要.

研究的目的:

为了确定FRA1作为黑色素瘤转移的驱动因素.
为了阐明FRA1介导转移的分子机制.
评估针对FRA1及其下游基因的治疗策略.

主要方法:

多omics集成以确定FRA1的转录目标.
在体外测试以评估FRA1点在入侵中的作用.
在体内对FRA1基因的药理抑制.
对FRA1和目标基因表达与患者存活率的相关性分析.

主要成果:

FRA1显著增强了黑色素瘤转移的开始和进展.
AXL,CDK6和FSCN1被确定为FRA1.1的关键转录标.
增加AXL,CDK6和FSCN1的表达与患者的不良结果相关.
沉默或抑制AXL,CDK6和FSCN1取消了FRA1介导的入侵和转移.
药理抑制CDK6和FSCN1抑制转移和延长存活时间.

结论:

FRA1是黑色素瘤转移的一个强有力的可操作的驱动因素.
包括AXL,CDK6和FSCN1在内的FRA1介导的转录网络对于癌症进展至关重要.
准FRA1及其下游基因为黑色素瘤和潜在的其他癌症提供了一个有希望的治疗途径.

更多相关视频

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

相关概念视频

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...